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Nebuliser therapy in the intensive care unit
M J O’Doherty, S H L Thomas
Nebulised drug therapy may be less eVective dose inhalers, rather than nebulisers.14 These
are attached to an adapter in the ventilatorin patients undergoing mechanical ventilation
than in those spontaneously breathing for two circuit and actuated during lung inflation. The
method is simple and treatments can be ad-main reasons – firstly, ventilated patients often
have severe lung disease associated with airway ministered rapidly. The amount of drug reach-
ing the lungs has been estimated as 1.5–2% inplugging and collapsed segments which limit
the spread of aerosols to aVected areas, and infants12 15 and 3.9–5.6% in adults.16 17 Ad-
ministration using a metered dose inhaler issecondly, aerosol deposition from nebulisers
and metered dose inhalers is reduced during increased by using an aerosol holding cham-
ber17 and this method may be more eYcientmechanical ventilation compared with spon-
taneous breathing.1 This is due to a number of than using an inspiratory phase activated jet
nebuliser.16 Arnon et al18 found that the use offactors including the site of the nebuliser in the
ventilator circuit, the ventilator settings, the a metered dose inhaler and an Aerochamber
(MV15, Trudell Medical, Canada), attachedmethod of triggering of the nebuliser, and the
size of the endotracheal tube. The indications between the Y piece and the endotracheal tube,
delivered larger amounts of budesonide to afor nebuliser therapy in mechanically ventilated
patients are given in table 1. filter in an in vitro ventilator circuit than either
an MAD2 nebuliser or an Ultravent nebuliser.In ventilated patients compliance is not a
problem and it is not necessary for nebulised Another study in ventilated patients with air-
ways obstruction has shown that a 270 lg dosetreatments to be completed rapidly. Indeed,
continuous nebulisation may be appropriate of salbutamol given via a metered dose inhaler
produces a similar increase in passive expiratoryfor some conditions so nebulisers need not be
selected on the basis of rapid output char- flow rate to that produced by a 2.5 mg dose
given by a jet (Upmist) nebuliser.19acteristics.
Jet nebulisers tend to leak around their join- The factors which appear to increase aerosol
delivery to the mechanically ventilated patienting parts, especially when used in conjunction
with a ventilator. The back pressure necessary from metered dose inhalers are the use of a
holding chamber,17 18 20 locating the meteredto cause leaks should be documented by the
manufacturer and users should be encouraged dose inhaler adapter on the inspiratory limb of
Departments of to use systems which do not leak. There is also the circuit rather than immediately adjacent
Nuclear Medicine,
a need to determine the nebuliser outputs and to the endotracheal tube,17 20 the absence ofHaemophilia and
Medicine, the particle size produced when attached to humidification,21 22 activation during lung in-
St Thomas’ Hospital, short inspiratory triggered nebulisation. flation,23 the use of larger bore endotracheal
London Nebulisers used in ventilator circuits should tubes,23 and a reduced lung inflation rate.23and Department of
not be left permanently in line and should beNuclear Medicine,
Kent and Canterbury cleaned and changed between nebulisations to
Hospital, avoid small particle bacterial aerosols.13 SuitableCanterbury, Kent, UK jet nebulisers
filters should be placed between the ventilatorM J O’Doherty Jet nebulisers can be used during pressure lim-
circuit and the inspiratory and expiratory ports ited or volume cycled ventilation. During vol-Wolfson Unit of of the ventilator to protect the valves in theClinical ume cycled ventilation the ventilator can only
ventilator from the eVects of deposited aerosol.Pharmacology, be driven during lung inflation. As the gas used
University of
to drive the nebuliser forms a proportion of theNewcastle,
Newcastle-upon-Tyne patient’s tidal volume, its volume and oxygenMethods of aerosol administrationNE2 4HH, UK content must be appropriate for each in-
S H L Thomas metered dose inhalers dividual. During pressure limited ventilation
Bronchodilators and steroids can be deliveredCorrespondence to: the nebuliser can be driven continuously. Jet
Dr S H L Thomas. during mechanical ventilation using metered nebulisers are widely available and cheap, but
many are not designed for use during vent-
ilation and leak, particularly at high inflationTable 1 Indication for use of nebulisers in patients receiving mechanical ventilation
pressures. During pressure support ventilationIndication Drug type
the use of a continuously running jet nebuliser
Of probable value may prevent a patient from being able to initiateBronchospasm/asthma [B] b2 agonists (salbutamol, terbutaline, etc.)2–4
Anticholinergic drugs (ipratropium bromide)2 5 a ventilator breath as the nebuliser interferes
Of possible value with the achievement of the negative pressureRespiratory syncytial virus Tribavirin (ribavirin)6
infection in infants [C] required.24
Bronchopulmonary dysplasia Corticosteroids7 Aerosol deposition from jet nebulisers hasin infants [C]
Adult and infant respiratory Surfactants (beractant, colfosceril palmitate, been measured in vivo as 1.2–3.0% in
distress syndrome [C] poractant alfa, pumactant)8–10 adults.16 25–27 In vivo data are lacking in infants.Pulmonary infection [C] Antibiotics11
Pulmonary hypertension [C] Prostacyclin12 For tribavirin administration the continuous
use of the small particle aerosol generator[B] and [C] indicate strength of evidence in terms of scientific validity (see Appendix 4 on page
S22). (SPAG), consisting of a jet nebuliser and par-
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ticle drying tube, is clinically proven although propriate for mechanically ventilated patients:
deposition associated with this apparatus is 1. Administration by metered dose inhaler into
unknown and delivery in vitro is poor. a spacer connected to the inspiratory limb of
Several factors may improve aerosol delivery the ventilator circuit with actuation at the onset
to the mechanically ventilated subject from jet of lung inflation. Humidification should be
nebulisers. Placing the nebuliser in the in- interrupted for a few minutes before ad-
spiratory limb of the ventilator circuit rather ministration.
than at the catheter mount connection or on the 2. Use of an inspiratory phase activated jet
expiratory limb increases delivery.28 29 However, nebuliser connected to an aerosol holding
placing the nebuliser too far from the patient chamber placed on the inspiratory limb of the
(>30 cm) may increase deposition on the circuit circuit, or at least connected by a T piece in
and reduce delivery.30 Delivery is also increased the inspiratory tubing no more than 30 cm from
by inspiratory triggered nebulisation,29 in- the Y piece. A high nebuliser gas flow should
creasing the fill in the nebuliser,27 interrupting be used and the drug solution should be diluted
humidification during nebulisation,22 31 and at- to fill the nebuliser to capacity. Humidification
taching the nebuliser to a spacer in the in- should be discontinued for a few minutes before
spiratory limb.25 27 28 Alteration of the ventilator and throughout nebulisation.
settings also aVects deposition which is in- 3. Use of an ultrasonic nebuliser connected tocreased by decreasing the respiratory rate, in-
the inspiratory limb of the circuit. The drugcreasing the inspiratory time, and by decreasing
solution should be diluted to fill the nebuliserminute ventilation.25 27 28 In spontaneously
to capacity and humidification should be dis-breathing subjects the use of positive end-ex-
continued for a few minutes before andpiratory pressure (PEEP) can increase the im-
throughout nebulisation.provements in lung function provided by
inhaled salbutamol,32 but use during mech-
anical ventilation will increase peak airways
Clinical evidence of benefit from drugpressure and may also worsen air trapping
aerosolsassociated with severe bronchospasm.33 Small
Evidence that can be used in assessing theparticles are associated with increased pen-
potential value of nebulised therapy in ventil-etration of endotracheal tubes34 and nebulisers
ated patients, in order of importance, is aswhich produce these may be associated with
follows:37 (1) clinical trials using clinically rel-higher pulmonary deposition.35
evant end points such as survival, length of stay
in ITU, length of stay in hospital; (2) clinical
trials using physiological measurements suchultrasonic nebulisers
as changes in airway resistance or lung com-Ultrasonic nebulisers can be used during all
pliance; (3) aerosol deposition and depositiontypes of mechanical ventilation. They are sim-
pler to use than jet nebulisers as no gas flow measurements in vivo in man using radio-
is required and many have large capacities. labelled aerosols; (4) aerosol deposition meas-
Disadvantages are that in theory some drugs urements in animals (these are particularly
might not be stable during ultrasonic nebu- appropriate for paediatric studies although not
lisation and the process may produce erroneous all lung conditions aVecting infants can be
automated measurements of tidal volume. Pul- mimicked in the lungs of healthy animals and,
monary aerosol deposition in vivo associated furthermore, the airway structure of animals
with ultrasonic nebulisers has been estimated diVers from that of human infants and therefore
as 1.3% in infants using the Penta- the distribution of aerosol may be diVerent);
sonic. In vivo data are lacking in adults but (5) aerosol delivery measurements made in vivo
in vitro data indicate that delivery through by measuring urinary excretion of nebulised
an endotracheal tube during volume cycled drugs although measurements may be aVected
ventilation can be as high as 22% using the by other factors such as renal or liver function;
Samsonic ultrasonic nebuliser, an 18 ml fill (6) aerosol delivery measurements made in
volume, and an aerosol storage chamber.36 vitro or using combined in vivo/in vitro methods
Under similar conditions the system 22 Acorn using radiolabelled or fluorescent aerosols.
jet nebuliser delivers 10%.28 These are inevitably overestimates of in vivoThe factors that appear to improve aerosol lung deposition.delivery using ultrasonic nebulisers include pla-
An ideal approach is a combination of thesecing the nebuliser in the inspiratory limb of the
methods. In vitro studies can select those nebu-ventilator circuit rather than at the catheter
lisers worthy of consideration for delivering amount connection or on the expiratory limb,26
particular drug, and then deposition and clin-increasing the fill in the nebuliser,28 36 attaching
ical outcome can be demonstrated in a par-the nebuliser to a spacer in the inspiratory
ticular clinical situation. The amount of druglimb,28 36 and alteration of the ventilator settings
deposited is estimated to prove that suYcient– for example, decreasing the respiratory rate,
drug is being deposited for clinical benefit.increasing the inspiratory time, or decreasing
There are few published studies proving thethe minute ventilation.36 Drugs have to be
eYcacy of aerosol drug treatments in ventilatedshown to be stable during ultrasonic nebu-
patients and it is often necessary to make clin-lisation.
ical judgements on the need for aerosol therapy
using clinical trial data from spontaneously
breathing subjects. This information is used,Recommended practice
together with lung deposition or delivery dataAny of the following three methods of aerosol
administration currently appear to be ap- from patients receiving mechanical ventilation,
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Table 2 Nebulisers for which there are research data on deposition achieved with been commenced too late for maximum benefit
nebulised saline, water, or drug solutions in the second study. Neither study included
Nebuliser Manufacturer Reference patients with apnoea and the eVects of nebu-
lised tribavirin in this group have not beenAcorn jet nebuliser System 22, Medic-Aid, Pagham, 25, 27, 28
Sussex, UK assessed. Further studies using larger patient
Samsonic DP Medical, Meylan, France 36 numbers, diVerent doses, and diVerentDP100 DP Medical, Meylan, France 36
Aerotech II CIS-US. Bedford, MA, USA 22 methods of administration will be needed to
Twin-jet Puritan-Bennet, Carlsbad, CA, USA 16, 22 clarify the role of nebulised tribavirin in severeRespirgard II Marquest, Englewood, CO, USA 22
Power mist Hospitak, Lindenhurst, NY, USA 22 RSV infection. This topic is discussed further in
Whisper Marquest, Englewood, CO, USA 6 the chapter on nebuliser treatment in childhoodUltraNeb DeVilbiss, UK 36
Ultravent Mallinckrodt, St Louis, MO, USA 18, 35 on pages S78–88.
Low flow nebuliser Baxter Healthcare, McGaw Park, IL, USA 9 The SPAG, as well as being cumbersomeMAD2 Astra Meditec, Lund, Sweden 18
to use, is an ineYcient method for delivering
aerosol (0.1 ll/min) compared with other
methods and its particle size output is com-
paratively large (mass median aerodynamic dia-to try and predict the usefulness of treatment.
Apparatus for which there are research data on meter (MMAD) 6.8 lm).45 Other devices may
be better for delivering tribavirin but this hasdelivery or lung deposition during mechanical
ventilation are shown in table 2. yet to be proved.
Tribavirin may deposit in ventilator circuits
and block the expiratory valve, leading to ex-
piratory pressures and barotrauma. This shouldbronchospasm
Nebulised b2 agonists are eVective for acute be avoided by appropriate use of filters to
protect the ventilator from the eVects of thesevere asthma in spontaneously breathing
patients38 and their use during mechanical vent- aerosol.
ilation can also improve measurements of pul-
monary function (respiratory system resistance,
compliance) in adults1 2 39 and infants3 with bronchopulmonary dysplasia
acute asthma, although not all studies have Nebulised beclomethasone 50 lg eight hourly
shown this.40 Pulmonary function can also be for 28 days reduced airways resistance and
improved in adults with chronic obstructive increased dynamic compliance in infants with
pulmonary disease.39 41 No clinical trials have bronchopulmonary dysplasia.6 Beclometha-
been performed to compare diVerent broncho- sone was administered using a Whisper
dilators or methods of aerosol administration. (Marquest Medical Products, Englewood, Co-
In some patients delivery of aerosol to peri- lorado, USA) jet nebuliser on the inspiratory
pheral bronchioles may be particularly poor limb of the circuit and running at 4–8 l/min of
because of intense bronchospasm and it may humidified gas. Pulmonary deposition was not
often be appropriate to use intravenous as well measured. Beclomethasone dipropionate
as inhaled bronchodilators in patients with nebuliser solution is no longer produced but it
severe disease. is to be expected that beclomethasone delivered
Ipratropium bromide also improves pul- by metered dose inhaler or an alternative nebu-
monary function in mechanically ventilated lised steroid such as budesonide should provide
patients with COPD.1 4 42 similar benefit. Further studies confirming the
value of this form of treatment are needed.
respiratory syncytial virus (rsv) infection
Clinical trials have been performed in infants adult respiratory distress syndrome
with respiratory failure associated with RSV (ards)
infection, evaluating the eYcacy of continuous Preliminary evidence suggests that nebulised
nebulisation of tribavirin (20 mg/ml) using the colfosceril palmitate (40–80 mg) given con-
SPAG.43 This consists of a jet nebuliser coupled tinuously over five days may improve the al-
to a particle drying tube. In one study5 infants veolar-arterial oxygen tension gradient
treated with nebulised tribavirin had reduced (A–aDo2) and fractional inspired oxygen (Fio2)
durations of mechanical ventilation, oxygen and reduce mortality in adults with sepsis-
treatment, and hospital stay compared with induced ARDS.9 Weg et al 8 also used nebulised
infants treated with nebulised water. In a sec- colfosceril palmitate in a group of patients with
ond study44 infants treated with nebulised tri- ARDS for 12 or 24 hours per day and found
bavirin had small reductions in the duration of a trend towards improvement in mortality com-
mechanical ventilation, supplemental oxygen pared with no treatment.
use, and hospital stay compared with those Nebulised orciprenaline (metaproterenol)
receiving nebulised saline. However, the has been shown to reduce airways resistance
diVerences were not statistically significant, al- in patients with ARDS.46
though a clinically relevant drug eVect may
have been missed because of reduced study 1 Everard ML, Stammers J, Hardy JG, Milner AD. New
aerosol delivery system for neonatal ventilator circuits.power. Other possible explanations for the ap- Arch Dis Child 1992;67:826–30.
2 Fernandez A, Lazaro A, Garcia A, Aragon C, Cerda E.parent diVerences in the findings of these stud-
Bronchodilators in patients with chronic obstructive pul-ies are that the nebulised water used as a monary disease on mechanical ventilation: utilisation of
metered dose inhalers. Am Rev Respir Dis 1990;141:164–8.placebo in the first study may have had a
3 Gay PC, Rodarte JR, Tayyab M, Hubmayr RD. Evaluationdeleterious eVect on lung function. Al- of bronchodilator responsiveness in mechanically ventil-
ated patients. Am Rev Respir Dis 1987;136:880–5.ternatively, treatment with tribavirin may have
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